ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

rilvegostomig

Also written as “Rilvegostomig”, “AZD2936” and “AZD9592 + Rilvegostomig”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Biliary Tract Neoplasms · Carcinoma, Hepatocellular · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.

Drug pageRilvegostomig: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 26, 202324 company-led studies, 23 open or runningNext primary completion: May 4, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca2222 open or runningphase 3since Oct 26, 2023Dec 13, 2018May 4, 2027phase 2 · NCT04379596
Presage Biosciencesits history only21 open or runningearly phase 1since Sep 1, 2020Sep 1, 2020Dec 2031early phase 1 · NCT04541108
  • Named in AstraZeneca’s own pipeline as rilvegostomig, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Daiichi Sankyo and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 6 earlier studies, Dec 13, 2018 to Dec 7, 2022.

  1. Jul 21, 2022Named rilvegostomigINNProposed as its International Nonproprietary Name in WHO's List 127 · before, AZD2936
  2. Mar 2, 2023Phase 2 study in Carcinoma, HepatocellularNCT05775159 · 294 enrolled · United States, China, Hong Kong and more
  3. Oct 26, 2023Phase 3 study in Biliary Tract NeoplasmsNCT06109779 · 760 enrolled · United States, Australia, Belgium and more
  4. Apr 5, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06357533 · 675 planned · United States, Australia, Austria and more
  5. May 21, 2024Phase 3 study in Biliary Tract NeoplasmsNCT06467357 · 620 planned · United States, Australia, Austria and more
  6. Aug 7, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06564844 · 25 enrolled · United States, Brazil, Canada and more
  7. Oct 3, 20242 phase 3 studiesNCT06627647, NCT06692738
  8. Dec 12, 2024Phase 3 study in HER2-positive Gastric CancerNCT06764875 · 840 planned · United States, Argentina, Australia and more
  9. Mar 7, 20253 phase 3 studiesNCT06868277, NCT06989112, NCT06921785
  10. May 5, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06996782 · 152 planned · United States, Belgium, Brazil and more
  11. Sep 3, 2025Phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT07161414 · 40 planned · United States, South Korea, Spain and more
  12. Oct 1, 2025Phase 3 study in Biliary Tract NeoplasmsNCT07221253 · 1,100 planned · United States, Australia, Belgium and more
  13. Jan 16, 2026Phase 3 study in Stomach NeoplasmsNCT07431281 · 2,130 planned · United States, Australia, Austria and more
  14. Jun 10, 2026Phase 3 study in Carcinoma, Transitional CellNCT07720284 · 915 planned · United States, Australia, Brazil and more
  15. Nov 10, 2026Primary completion moved from 2026-08-28 to 2028-06-01Date moved laterphase 2 · +21 months · NCT04995523

Ahead

  1. May 4, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT04379596
  2. Jul 19, 2027Primary completion: phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT07161414
  3. Sep 29, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05123482
  4. Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT05702229

TargetBeta

“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory …”NCIt, read by Claude
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory mot”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315

Studies

All 22 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07720284Carcinoma, Transitional Cell · United States, Australia, Brazil and more3RecruitingSep 11, 2030915
NCT07431281Stomach Neoplasms · United States, Australia, Austria and more3RecruitingAug 16, 20292,130
NCT07221253Biliary Tract Neoplasms · United States, Australia, Belgium and more3RecruitingJul 31, 20291,100
NCT07161414Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, South Korea, Spain and more1RecruitingJul 19, 202740
NCT06996782Carcinoma, Non-Small-Cell Lung · United States, Belgium, Brazil and more2RecruitingFeb 23, 2029152
NCT06921785Carcinoma, Hepatocellular · United States, Australia, Brazil and more3RecruitingMar 15, 20301,220
NCT06989112Endometrial Neoplasms · United States, Australia, Austria and more3RecruitingJan 19, 2029600
NCT06868277Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingJan 17, 2030830
NCT06764875HER2-positive Gastric Cancer · United States, Argentina, Australia and more3RecruitingApr 27, 2029840
NCT06692738Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingJul 1, 20301,160
NCT06627647Non-squamous Non-small Cell Lung Cancer · United States, Argentina, Australia and more3RecruitingNov 18, 20301,160
NCT06564844Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more3Active, not recruitingJul 10, 202625
NCT06467357Biliary Tract Neoplasms · United States, Australia, Austria and more3RecruitingJun 12, 2028620
NCT06357533Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3RecruitingDec 28, 2029675
NCT06109779Biliary Tract Neoplasms · United States, Australia, Belgium and more3Active, not recruitingJan 2, 2029760
NCT05775159Carcinoma, Hepatocellular · United States, China, Hong Kong and more2Active, not recruitingOct 27, 2026294
NCT05702229Stomach Neoplasms · United States, China, Japan and more2RecruitingNov 30, 2027163
NCT05123482Breast Neoplasms · United States, Australia, Belgium and more2RecruitingSep 29, 2027460
NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2RecruitingMay 28, 2030630
NCT04995523Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more2Active, not recruitingJun 1, 2028212
NCT04379596Stomach Neoplasms · United States, Brazil, Canada and more2Active, not recruitingMay 4, 2027452
NCT03819465Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more1Active, not recruitingMay 23, 2023175

How it is read

Names in the registry

  • “Rilvegostomig”, 20 entries
  • “AZD2936”, 2 entries
  • “AZD9592 + Rilvegostomig”, 2 entries
  • “AZD8205 and AZD2936 (Rilvegostomig)”, 1 entry
  • “AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.